VIRxSYS Corporation Awarded Maryland Stem Cell Grant

GAITHERSBURG, Md.--(BUSINESS WIRE)--VIRxSYS Corporation announced today that the company has received a grant from the Maryland Stem Cell Research Commission to develop safer methods for induced pluripotent stem cell (iPS) using the company’s proprietary spliceosome-mediated RNA trans-splicing (SMaRT™) and lentiviral gene delivery platform technologies.
MORE ON THIS TOPIC